When does genomics become eugenics?
By Eben Kirksey,
Financial Review
| 12. 11. 2020
As the tools to identify human traits and manipulate them become more refined, ideas about normalcy and deviancy, fitness and disability, are subtly changing.
Simply Google “BGI NIFTY” and you will find a slick website from China’s premier genomics company offering new options in the quest for quality children. This screening technology has already been used in more than 62 countries in Asia, Europe, the Americas, and the Middle East.
The NIFTY webpage has a “decision calculator” to see if you should mitigate the risks of your pregnancy. An embedded YouTube video offers a perspective from a young white couple. They talk in British accents about the importance of accuracy, saying that they are willing to pay for the best prenatal care on the market. An older single woman says that this will be her first and perhaps only baby, and she wants to make sure that nothing is wrong.
Previously in China, under the controversial one-child policy, couples were encouraged to make the most of their only shot. Amniocentesis – the insertion of a needle through the abdominal skin into the uterus to extract amniotic fluid which is then tested – was promoted by government experts as part of the practice...
see more
Related Articles
By Marcy Darnovsky, Katie Hasson, and Timothy M. Krahn, The CRISPR Journal | 02.19.2021
Levrier apparently misunderstands the nature of our project published in The CRISPR Journal in October 2020.1 We identified and reviewed policy documents relevant to human germline and heritable genome editing research in 96 countries.
By Adam Feuerstein, STAT | 02.16.2021
Bluebird Bio said Tuesday that it has suspended clinical trials involving its gene therapy for sickle cell disease after receiving reports that two patients treated with the one-time therapy were diagnosed with cancer.
The trials were placed on “temporary suspension”...
By Jocelyn Kaiser, Science | 02.16.2021
A company has stopped its clinical studies of a promising gene therapy for the blood disorder sickle cell disease after two people who participated developed leukemia-like cancer. Bluebird bio is now investigating whether a virus it uses to deliver a...
By Elizabeth Cooney, STAT | 02.17.2021
Image licensed under the CC BY 3.0
Novartis and the Bill and Melinda Gates Foundation are joining forces to discover and develop a gene therapy to cure sickle cell disease with a one-step, one-time treatment that is affordable and simple...